



CLEAN VERSION OF REWRITTEN OR ADDED CLAIMS
PURSUANT TO 37 CFR § 1.21 (c)(1)(i)

Please cancel Claim 26.

BEST AVAILABLE COPY

Please amend the following claims.

- C1
22. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is aerosolized for administration to a subject.

- C2
28. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is in an intratracheal instillation device, said instillation device is selected from the group consisting of an endotracheal tube and a bronchoscope for intratracheal administration to a subject.

Please add the following claims.

- C3
33. A composition for the treatment of a microbial infection comprising, a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is contained within a nebulizer.
34. The composition of Claim 33, wherein said leukotriene is leukotriene B₄.
35. The composition of Claim 33, wherein said leukotriene is cysteinyl leukotriene.
36. The composition of Claim 33, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄ and leukotriene E₄.
37. The composition of Claim 33, wherein said microbial infection comprises *Klebsiella pneumoniae* infection.



APPENDIX II
CLEAN VERSION OF THE ENTIRE SET OF PENDING CLAIMS
PURSUANT TO 37 CFR § 1.121 (c)(3)

22. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is aerosolized for administration to a subject.

BEST AVAILABLE COPY

23. The solution of Claim 22, wherein said leukotriene is leukotriene B₄.
24. The solution of Claim 22, wherein said leukotriene is a cysteinyl leukotriene.
25. The solution of Claim 24, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄, and leukotriene E₄.
27. The solution of Claim 22, wherein said microbial infection comprises *Klebsiella pneumoniae* infection.
28. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is in an intratracheal instillation device, said instillation device is selected from the group consisting of an endotracheal tube and a bronchoscope for intratracheal administration to a subject.
29. The solution of Claim 28, wherein said leukotriene is leukotriene B₄.
30. The solution of Claim 28, wherein said leukotriene is a cysteinyl leukotriene.
31. The solution of Claim 28, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄, and leukotriene E₄.
32. The solution of Claim 28, wherein said microbial infection comprises *Klebsiella pneumoniae* infection.